Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
03 nov 2015 - 07:00
Statutaire naam
Kiadis Pharma N.V.
Titel
Data from Kiadis Pharma’s ongoing Phase II trial with ATIR101™ will be presented at the American Society of Hematology 2015 Annual Meeting
Bericht
Amsterdam, The Netherlands, November 3, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that data from the Company’s ongoing Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™ has been selected by the American Society of Hematology (ASH) Program Committee for presentation at the 57th Annual Meeting in Orlando, Florida on December 7, 2015.
The abstract provides data on Kiadis Pharma’s international multi-center study, in which a total of 23 leukemia patients, including patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), have been enrolled to be treated with ATIR101™ as part of their transplant regimen. In addition, the abstract includes a comparison to a historic control group.
Title: Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen
Date: Monday, December 7, 2015 from 6:00 to 8:00 PM EST
Number: 4391
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Location: Orange County Convention Center, Hall A
The abstract is scheduled to be available at www.hematology.org on Thursday, November 5, 2015 at 9:00 AM Eastern Standard Time (EST). In addition, the abstract will be published online in the December 3, 2015 supplemental volume of Blood.
Datum laatste update: 27 juli 2024